Tirzep 7.5 mg (Tirzepatide) Tablets

Introduction

Tirzep 7.5 mg (Tirzepatide) is an intermediate-strength therapeutic formulation of a first-in-class dual metabolic pathway therapy classified as a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Manufactured by ACI Pharmaceuticals PLC and distributed globally by Onco Solution, Tirzep 7.5 mg serves as a critical bridge and maintenance tier in metabolic treatment. This strength is engineered for patients who require intensified glycemic stabilization and advanced adipose tissue reduction beyond the baseline maintenance level, optimizing insulin sensitivity and energy balance.

Indications

Tirzep 7.5 mg (Tirzepatide) is indicated for:

• Glycemic Optimization: Improving blood glucose control in adult patients with Type 2 Diabetes Mellitus as an adjunct to diet and exercise when lower doses are insufficient.
• Chronic Weight Management: Adjuvant therapy alongside a reduced-calorie diet and increased physical activity for long-term weight reduction in adults with an initial BMI $\ge 30 \text{ kg/m}^2$ (obesity) or $\ge 27 \text{ kg/m}^2$ (overweight) accompanied by at least one weight-related medical comorbidity (e.g., hypertension, dyslipidemia, or severe insulin resistance).

Pharmacology

Tirzepatide, the active molecule in Tirzep, is a synthetic, single peptide chain consisting of 39 amino acids, chemically bound to a C20 fatty diacid moiety that extends its systemic therapeutic window to a 5-day half-life via structural albumin binding.

• Dual Action Mechanism: Unlike traditional single GLP-1 receptor agonists, Tirzep binds directly to and activates both native GIP and GLP-1 cell surface receptors.
• Physiological Response: At this 7.5 mg mid-tier concentration, it exerts robust control over glucose-dependent insulin secretion and suppresses inappropriate glucagon release. Concurrently, it slows gastric emptying, improves insulin sensitivity across peripheral tissues, and targets central nervous system pathways in the hypothalamus to optimize satiety signaling and lower overall caloric intake.

Dosage & Administration

Subcutaneous (SC) Injection Administration Only:

• Intermediate Maintenance Dosage: 7.5 mg injected subcutaneously once weekly.
• Titration Context: The 7.5 mg strength is a step-up dose. Patients must never initiate treatment at this strength. Patients must remain on the 5 mg weekly dose for a minimum of 4 weeks before escalating to this 7.5 mg dose to ensure proper gastrointestinal adjustment. If further glycemic control or weight management is required, the dose can be up-titrated to 10 mg after a minimum of 4 weeks at this strength.
• Method of Use: Inject subcutaneously once weekly at any time of day, completely independent of food. Administer into the fatty tissue of the abdomen, thigh, or upper arm, ensuring injection sites are rotated weekly.
• Missed Dose Protocol: Administer as soon as remembered within 4 days (96 hours). If more than 4 days have elapsed, skip that dose entirely and proceed with the next regular weekly injection.

Drug Interactions

• Delayed Gastric Transit: Tirzep 7.5 mg slows gastric emptying, which may temporarily reduce the peak absorption rate and alter the systemic levels of concomitantly administered oral medications.
• Oral Contraceptives: Hormonal oral birth control methods may face compromised absorption. Patients should transition to a non-oral option or add a secondary barrier method for 4 weeks after initiating treatment or following dose escalation.
• Hypoglycemia Risk: Concomitant use with oral insulin secretagogues (e.g., sulfonylureas) or exogenous insulin increases the risk of hypoglycemia, requiring a defensive reduction of those co-prescribed agents.

Contraindications

• Thyroid Neoplasms: Strictly contraindicated in individuals with a personal or familial clinical history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Hypersensitivity: Known structural allergy or severe systemic reaction to Tirzepatide or any inactive stabilizing agents within the injection vehicle.

Side Effects

Patients receiving Tirzep 7.5 mg may experience:

• Gastrointestinal (Very Common): Mild-to-moderate nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and mild abdominal discomfort. These side effects can re-emerge temporarily when stepping up to the 7.5 mg dose but typically diminish within a few weeks.
• Systemic: Mild fatigue, injection site reactions (transient redness, bruising, or itching), and low blood sugar when paired with traditional diabetes therapies.
• Severe (Rare): Acute pancreatitis, severe gallbladder disease (cholecystitis), or acute kidney injury caused by dehydration from persistent GI side effects.

Pregnancy & Lactation

• Pregnancy: Clinical data is limited. Poorly managed maternal metabolic profiles present structural risks to the fetus. Discontinue Tirzep use if pregnancy is confirmed or actively planned.
• Lactation: Use with caution. The potential benefits to the nursing infant should be weighed against the therapeutic necessity of the drug for the mother.

Precautions & Warnings

• Pancreatitis Alert: Patients must be closely monitored for severe, persistent abdominal pain radiating to the back. Discontinue immediately if acute pancreatitis is suspected.
• Renal Parameter Tracking: Dehydration from nausea or diarrhea can lead to acute renal impairment. Ensure proper hydration and monitor kidney function metrics if gastrointestinal symptoms become severe during the treatment phase.
• Retinopathy Risks: Rapid improvements in long-term glycemic control can lead to a transient worsening of pre-existing diabetic retinopathy; routine ophthalmological exams are advised.

Use in Special Populations

• Pediatrics: Safety and pharmacological efficacy profiles have not been established for individuals under the age of 18.
• Geriatric Care: No empirical dose adjustments are required for elderly patients, although close tracking for gastrointestinal sensitivities is recommended during step-up phases.

Overdose Effects

An acute overdose of Tirzep 7.5 mg can induce profound gastrointestinal distress (severe, unremitting vomiting and diarrhea) alongside acute hypoglycemia. Management requires urgent hospital-based supportive care and continuous blood glucose tracking.

Storage

• Refrigeration Required: Store unused pre-filled syringes or pens between 2°C to 8°C (36°F to 46°F).
• Handling: Do not freeze. Discard the solution immediately if it has been frozen. Keep the product stored inside its original outer package to insulate it from direct light.

Supplier Information

Onco Solution is an established global pharmaceutical distributor, trusted for securing authentic, temperature-controlled supplies of next-generation metabolic and supportive cancer care therapies. For wholesale export quotes and logistics tracking, visit www.oncosolution.com.

Manufacturer Information

Tirzep 7.5 mg is manufactured under stringent quality controls by ACI Pharmaceuticals PLC, a premier pharmaceutical leader in Bangladesh renowned for its advanced manufacturing infrastructure and international regulatory compliance.